NCT03341936 2025-06-18Neodjuvant Nivolumab and Lirilumab, Followed by Surgery, Followed by Adjuvant Nivolumab and Lirilumab, in SCCHNDana-Farber Cancer InstitutePhase 2 Active not recruiting29 enrolled 11 charts